M
Madeleine F. Jennewein
Researcher at Fred Hutchinson Cancer Research Center
Publications - 9
Citations - 1137
Madeleine F. Jennewein is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Epitope & Monoclonal antibody. The author has an hindex of 7, co-authored 9 publications receiving 567 citations.
Papers
More filters
Journal ArticleDOI
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
Leonidas Stamatatos,Leonidas Stamatatos,Julie Czartoski,Yu Hsin Wan,Leah J. Homad,Vanessa Rubin,Hayley Glantz,Moni B. Neradilek,Emilie Seydoux,Madeleine F. Jennewein,Anna J. MacCamy,Junli Feng,Gregory J. Mize,Stephen C. De Rosa,Stephen C. De Rosa,Andrés Finzi,Andrés Finzi,Maria P. Lemos,Kristen W. Cohen,Zoe Moodie,M. Juliana McElrath,M. Juliana McElrath,Andrew T. McGuire,Andrew T. McGuire +23 more
TL;DR: In this article, the authors examined whether sera from recovered and naive donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants.
Journal ArticleDOI
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
Emilie Seydoux,Leah J. Homad,Anna J. MacCamy,K. Rachael Parks,K. Rachael Parks,Nicholas K. Hurlburt,Madeleine F. Jennewein,Nicholas R. Akins,Andrew B. Stuart,Yu Hsin Wan,Junli Feng,Rachael E. Whaley,Suruchi Singh,Michael Boeckh,Michael Boeckh,Kristen W. Cohen,M. Juliana McElrath,M. Juliana McElrath,Janet A. Englund,Helen Y. Chu,Marie Pancera,Marie Pancera,Andrew T. McGuire,Andrew T. McGuire,Leonidas Stamatatos,Leonidas Stamatatos +25 more
TL;DR: Most anti-S antibodies that were generated in this patient during the first weeks of COVID-19 infection were non-neutralizing and target epitopes outside the RBD.
Journal ArticleDOI
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
Madeleine F. Jennewein,Anna J. MacCamy,Nicholas R. Akins,Junli Feng,Leah J. Homad,Nicholas K. Hurlburt,Emilie Seydoux,Yu-Hsin Wan,Andrew B. Stuart,Venkata Viswanadh Edara,Katharine Floyd,Abigail Vanderheiden,John R. Mascola,Nicole A. Doria-Rose,Lingshu Wang,Eun Sung Yang,Helen Y. Chu,Jonathan L. Torres,Gabriel Ozorowski,Andrew B. Ward,Rachael E. Whaley,Kristen W. Cohen,Marie Pancera,Marie Pancera,M. Juliana McElrath,M. Juliana McElrath,Janet A. Englund,Andrés Finzi,Mehul S. Suthar,Andrew T. McGuire,Andrew T. McGuire,Leonidas Stamatatos,Leonidas Stamatatos +32 more
TL;DR: In this paper, the authors characterized 198 antibodies isolated from four COVID-19+ subjects and identified 14 SARS-CoV-2 neutralizing antibodies, including N-terminal domain (NTD), epitope in S2, and 11 binding the receptor-binding domain (RBD).
Posted ContentDOI
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.
Emilie Seydoux,Leah J. Homad,Anna J. MacCamy,K. Rachael Parks,K. Rachael Parks,Nicholas K. Hurlburt,Madeleine F. Jennewein,Nicholas R. Akins,Andrew B. Stuart,Yu-Hsin Wan,Junli Feng,Rachael E Nelson,Suruchi Singh,Kristen W. Cohen,M. Juliana McElrath,M. Juliana McElrath,Janet A. Englund,Helen Y. Chu,Marie Pancera,Marie Pancera,Andrew T. McGuire,Andrew T. McGuire,Leonidas Stamatatos,Leonidas Stamatatos +23 more
TL;DR: The study indicates that the majority of antibodies against the viral envelope spike that were generated during the first weeks of COVID-19 infection are non-neutralizing and target epitopes outside the RBD.
Journal ArticleDOI
Designed proteins assemble antibodies into modular nanocages.
Robby Divine,Ha V. Dang,George Ueda,Jorge A. Fallas,Ivan Vulovic,William Sheffler,Shally Saini,Yan Ting Zhao,Infencia Xavier Raj,Peter A. Morawski,Madeleine F. Jennewein,Leah J. Homad,Yu Hsin Wan,Marti R. Tooley,Franziska Seeger,Ali Etemadi,Ali Etemadi,Mitchell L Fahning,James Lazarovits,Alex Roederer,Alexandra C. Walls,L. Stewart,Mohammadali Mazloomi,Neil P. King,Daniel J. Campbell,Andrew T. McGuire,Andrew T. McGuire,Leonidas Stamatatos,Leonidas Stamatatos,Hannele Ruohola-Baker,Julie Mathieu,David Veesler,David Baker +32 more
TL;DR: In this article, the computational design of nanocages in which one structural component is an antibody or Fc-ligand fusion and the second is a designed antibody-binding homo-oligomer that drives nanocage assembly is discussed.